Copy to clipboard 
Royal Biologics introduced FIBRI-CELL™ to enhance traditional bone graft substitutes for orthopedic fusion procedures. FIBRI-CELL complements the company’s FIBRINET technology, acquired from Vertical Spine earlier this year.
FIBRI-CELL utilizes Royal’s Osteo-Spin™ technology to deliver activated platelets, bone marrow aspirate and cortical fibers in an “ultra-hydrated” blend, creating a point of care live cellular bone graft option.
Combining autologous cells in a rapid point of care centrifugation preparation delivery system gives FIBRI-CELL a first-of-its-kind ability to create the ultimate live cellular graft during each surgical procedure.
Each FIBRI-CELL kit combines cortical fibers with the accessories needed to “ultra-hydrate” a graft sample in a centrifugation cycle that creates the ultimate live cellular option, optimizing maximum cellular content and handling ability. Osteo-Spin technology wicks and allows cells to adhere to the bone scaffold.
“We are advancing biologics in orthopedics with the release of FIBRI-CELL™ and our Osteo-Spin™ technology,” said Salvatore Leo, Chief Executive Officer of Royal Biologics. “We now have the ability to harness the power of each patient’s cells by combining activated autologous blood platelets and bone marrow aspirate growth factors in a next-generation scaffold. Osteo-Spin™ technology presents the unique ability to capture a patient’s cells, optimizing all unique growth factors, for superior wicking and handling characteristics. Traditional hydration of allograft and autograft is now enhanced by accelerating the adherence of cells to each scaffold.”
FIBRI-CELL™ is a complement to the Royal Biologics FIBRINET™ system, which creates a platelet-rich fibrin membrane (PRFM) from a patient’s autologous blood. The membrane discs can be utilized for fusion-based procedures in orthopedics.
Royal Biologics introduced FIBRI-CELL™ to enhance traditional bone graft substitutes for orthopedic fusion procedures. FIBRI-CELL complements the company's FIBRINET technology, acquired from Vertical Spine earlier this year.
FIBRI-CELL utilizes Royal's Osteo-Spin™ technology to deliver activated platelets, bone marrow aspirate and...
Royal Biologics introduced FIBRI-CELL™ to enhance traditional bone graft substitutes for orthopedic fusion procedures. FIBRI-CELL complements the company’s FIBRINET technology, acquired from Vertical Spine earlier this year.
FIBRI-CELL utilizes Royal’s Osteo-Spin™ technology to deliver activated platelets, bone marrow aspirate and cortical fibers in an “ultra-hydrated” blend, creating a point of care live cellular bone graft option.
Combining autologous cells in a rapid point of care centrifugation preparation delivery system gives FIBRI-CELL a first-of-its-kind ability to create the ultimate live cellular graft during each surgical procedure.
Each FIBRI-CELL kit combines cortical fibers with the accessories needed to “ultra-hydrate” a graft sample in a centrifugation cycle that creates the ultimate live cellular option, optimizing maximum cellular content and handling ability. Osteo-Spin technology wicks and allows cells to adhere to the bone scaffold.
“We are advancing biologics in orthopedics with the release of FIBRI-CELL™ and our Osteo-Spin™ technology,” said Salvatore Leo, Chief Executive Officer of Royal Biologics. “We now have the ability to harness the power of each patient’s cells by combining activated autologous blood platelets and bone marrow aspirate growth factors in a next-generation scaffold. Osteo-Spin™ technology presents the unique ability to capture a patient’s cells, optimizing all unique growth factors, for superior wicking and handling characteristics. Traditional hydration of allograft and autograft is now enhanced by accelerating the adherence of cells to each scaffold.”
FIBRI-CELL™ is a complement to the Royal Biologics FIBRINET™ system, which creates a platelet-rich fibrin membrane (PRFM) from a patient’s autologous blood. The membrane discs can be utilized for fusion-based procedures in orthopedics.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
